Evidence map›Paper›PMID 21850539›Full record

ReviewImmunologic research2011

Membrane attack by complement: the assembly and biology of terminal complement complexes.

Cosmin A Tegla, Cornelia Cudrici, Snehal Patel, Richard Trippe, Violeta Rus, Florin Niculescu, Horea Rus

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunologic research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 1 synthesis or guideline pooled it, 309 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Cosmin A TeglaDepartment of Neurology, School of Medicine, University of Maryland, 655 W. Baltimore Street, BRB 12-033, Baltimore, MD 21201, USA.
Cornelia Cudrici
Snehal Patel
Richard Trippe
Violeta Rus
Florin Niculescu
Horea Rus
University of Maryland, Baltimore · USVA Maryland Health Care System · US

Funding

Regulation of Oligodendrocyte SurvivalR01NS042011 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI RUS, HOREA · 2002 to 2006
$1.2M
NINDS NIH HHS R01 NS042011NINDS NIH HHS R01 NS42011
6 · The paper itself

Abstract

Complement system activation plays an important role in both innate and acquired immunity. Activation of the complement and the subsequent formation of C5b-9 channels (the membrane attack complex) on the cell membranes lead to cell death. However, when the number of channels assembled on the surface of nucleated cells is limited, sublytic C5b-9 can induce cell cycle progression by activating signal transduction pathways and transcription factors and inhibiting apoptosis. This induction by C5b-9 is dependent upon the activation of the phosphatidylinositol 3-kinase/Akt/FOXO1 and ERK1 pathways in a Gi protein-dependent manner. C5b-9 induces sequential activation of CDK4 and CDK2, enabling the G1/S-phase transition and cellular proliferation. In addition, it induces RGC-32, a novel gene that plays a role in cell cycle activation by interacting with Akt and the cyclin B1-CDC2 complex. C5b-9 also inhibits apoptosis by inducing the phosphorylation of Bad and blocking the activation of FLIP, caspase-8, and Bid cleavage. Thus, sublytic C5b-9 plays an important role in cell activation, proliferation, and differentiation, thereby contributing to the maintenance of cell and tissue homeostasis.

Indexed as

AnimalsApoptosisbcl-Associated Death ProteinBH3 Interacting Domain Death Agonist ProteinCaspase 8CDC2 Protein KinaseCell Cycle ProteinsCell MembraneComplement Membrane Attack ComplexCyclin BCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent KinasesForkhead Box Protein O1Forkhead Transcription FactorsG1 PhaseBAD protein, humanbcl-Associated Death ProteinBH3 Interacting Domain Death Agonist ProteinBID protein, humanCASP8 protein, humanCaspase 8CDC2 Protein KinaseCDK1 protein, humanCDK2 protein, humanCDK4 protein, humanCell Cycle ProteinsComplement Membrane Attack ComplexCyclin BCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent KinasesForkhead Box Protein O1Forkhead Transcription FactorsFOXO1 protein, humanMitogen-Activated Protein Kinase 3Muscle ProteinsNerve Tissue ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRGCC protein, human

Identifiers

PMID21850539
PMCPMC3732183
OpenAlexW1992665403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.